1. Pink Sheet
  2. >>Product Reviews

Schooled On Prilosec And Zelnorm: Ironwood/Forest Aim Linzess At OTC-Dominated Market

 
• By Emily Hayes

After FDA approval of Linzess, the commercial challenge of competing with over-the-counter laxatives begins. Ironwood is well-versed on the success story of proton pump inhibitors and the mixed record of withdrawn constipation/IBS drug Zelnorm when it comes to introducing a branded drug into the market.

Explaining the commercial strategy for newly FDA-approved IBS/constipation drug Linzess (linaclotide), Ironwood Pharmaceuticals Inc. cites experience with branded proton pump inhibitors, among other classes, as successful models for breaking into GI markets dominated by cheap over-the-counter products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews